Centre for Innovative Cancer Research, Ottawa Hospital Research Institute.
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.
J Immunother. 2018 Apr;41(3):125-129. doi: 10.1097/CJI.0000000000000208.
Anticancer vaccination is becoming a popular therapeutic approach for patients with cancers expressing common tumor antigens. One variation on this strategy is a heterologous virus vaccine where 2 viruses encoding the same tumor antigen are administered sequentially to prime and boost antitumor immunity. This approach is currently undergoing clinical investigation using an adenovirus (Ad) and the oncolytic virus Maraba (MRB). In this study, we show that Listeria monocytogenes can be used in place of the Ad to obtain comparable immune priming efficiency before MRB boosting. Importantly, the therapeutic benefits provided by our heterologous L. monocytogenes-MRB prime-boost strategy are superior to those conferred by the Ad-MRB combination. Our study provides proof of concept for the heterologous oncolytic bacteria-virus prime-boost approach for anticancer vaccination and merits its consideration for clinical testing.
癌症疫苗接种正成为表达常见肿瘤抗原的癌症患者的一种热门治疗方法。这种策略的一种变体是异源病毒疫苗，其中两种编码相同肿瘤抗原的病毒依次给予以启动和增强抗肿瘤免疫。目前正在使用腺病毒 (Ad) 和溶瘤病毒 Maraba (MRB) 进行这种方法的临床研究。在这项研究中，我们表明李斯特菌可以替代 Ad 来获得 MRB 增强之前相当的免疫启动效率。重要的是，我们的异源李斯特菌-MRB 初免-加强策略提供的治疗益处优于 Ad-MRB 联合提供的益处。我们的研究为溶瘤细菌-病毒初免-加强抗癌疫苗接种的异源方法提供了概念验证，并值得考虑进行临床测试。
